Low rates of chlamydia retesting post-treatment are hampering the campaign to prevent reinfections and reproductive complications, Australian doctors say.  

Better contact tracing and diagnosis of pelvic inflammatory disease (PID) are also among the priorities, according to Dr Stephanie Murani and her colleagues at the Burnet Institute and the University of Melbourne.  

Chlamydia remains one of the most notified bacterial STIs in Australia, with the number of notifications rising by 21% from 2014 to 2018, they write in the Medical Journal of Australia.  

Current Australian STI management guidelines advise repeat testing at three months post-treatment to identify possible reinfection, but Dr Murani’s team say low retesting rates are a key gap in chlamydia prevention and management.